Cardiovascular

Home

About

Cardiovascular Program

Cardiovascular_program

Funding

  • NHLBI
  • NIAID

The Cardiovascular and Metabolic Program aims at advancing the knowledge of prevalent cardiovascular and metabolic diseases and accelerating the development of new therapeutic and diagnostic strategies. The program brings together scientists from multiple communities within MGH and Harvard. Collectively, the projects described below undertake a variety of systems-level analyses, including systematic mapping of genetic/functional interactions, functional genomics, and in vivo molecular imaging.

Atherosclerosis/Myocardial infarction

  • Exploring the role of inflammatory networks in ischemic heart disease and stroke
  • Major focus on monocyte/macrophage subsets, their function and ontogeny
  • Chemical biology and genomic studies to assign function to susceptibility alleles for atherosclerosis or myocardial infarction
  • Nanomaterial-based molecular imaging probes to define cellular and enzymatic components of plaque, and monitor disease progression and therapeutic response in pre-clinical studies and clinical trials

Metabolism and energetics

  • Systematic mapping of metabolic pathways in health and disease using mass spectrometry-based metabolomics and proteomics
  • Translational research in metabolic syndrome
  • Functional genomics of mitochondrial function in diabetes and other human diseases

Stem cells and regeneration

  • Role of hematopoietic stem cells in ischemic heart disease and stroke
  • Small molecule approaches to direct differentiation of stem cells into the cardiac lineage
  • Chemical screens in stem cells or model organisms to dissect developmental pathways and manipulate them for therapeutic benefit
  • Nanoparticle-based imaging of transplanted stem cells in vivo

Novel biomarkers for diagnosis, clinical phenotyping and disease status

  • Metabolites
  • Cell-based phenotypes
  • Nanoparticle-based molecular imaging
  • Benchtop parallel measurement of multiplexed analytes

Recent Publications (more...)

Alaarg A, Pérez-Medina C, Metselaar JM, Nahrendorf M, Fayad ZA, Storm G, Mulder WJM
Applying nanomedicine in maladaptive inflammation and angiogenesis.
Adv Drug Deliv Rev. 2017;:ePub - PMID: 28506745
Xing L, Higuma T, Wang Z, Aguirre AD, Mizuno K, Takano M, Dauerman HL, Park SJ, Jang Y, Kim CJ, Kim SJ, Choi SY, Itoh T, Uemura S, Lowe H, Walters DL, Barlis P, Lee S, Lerman A, Toma C, Tan JWC, Yamamoto E, Bryniarski K, Dai J, Zanchin T, Zhang S, Yu B, Lee H, Fujimoto J, Fuster V, Jang IK
Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A 4-Year Follow-Up Study.
J Am Coll Cardiol. 2017;69(20):2502-2513 - PMID: 28521888
Meyer IS, Jungmann A, Dieterich C, Zhang M, Lasitschka F, Werkmeister S, Haas J, Müller OJ, Boutros M, Nahrendorf M, Katus HA, Hardt SE, Leuschner F
The cardiac microenvironment uses non-canonical WNT signaling to activate monocytes after myocardial infarction.
EMBO Mol Med. 2017;:ePub - PMID: 28774883

Recent News (more...)

2017-07-21: "..changing from racing a Ferrari to riding a bicycle (with a flat tire)" - former CBS fellow Florian Leuschner is documenting his transition from a postdoctoral fellowship in the United States to junior faculty in Europe in this Circulation Research paper. (pdf)
2017-07-10: Recent CSB work featured in the NEJM. (pdf)
2017-06-27: The Nahrendorf and Swirski labs at the 2017 Atherosclerosis Gordon Conference, which elected Fil Swirski as 2021 conference chair.
2017-05-17: Michael Dworkin (Higgins Lab) won a best poster award for his poster “Improved estimation of average glucose from HbA1c by adjusting HbA1c for RBC age” at the 2017 Harvard Medical School Pathology Annual Retreat.
2017-05-05: American Heart Association selected Fil Swirski, PhD to receive the 2017 Jeffrey M. Hoeg Award for Basic Science & Clinical Research. Congratulations, Fil!